Literature DB >> 11018722

Suppression of urokinase-type plasminogen activator expression from human ovarian cancer cells by urinary trypsin inhibitor.

H Kobayashi1, M Suzuki, G W Sun, Y Hirashima, T Terao.   

Abstract

Urinary trypsin inhibitor (UTI), a Kunitz-type protease inhibitor, efficiently inhibits tumor cell invasion and metastasis. We examined the effect of UTI on urokinase-type plasminogen activator (uPA) expression in ovarian cancer cell lines, HOC-I and HRA. By Northern blot, Western blot, ELISA, and zymographic analyses, we demonstrated that UTI inhibited the expression of uPA mRNA and protein in these cells in a time- and dose-dependent manner, independent of whether induction was triggered by phorbol ester. Monoclonal antibody 4G12, which inhibits UTI binding to the cells, produced a dose-dependent abrogation in UTI-mediated down-regulation of uPA expression. These data suggest that UTI significantly down-regulates tumor cell uPA mRNA expression and protein secretion, and that UTI binding to the cells is necessary to exert the UTI's action.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11018722     DOI: 10.1016/s0167-4838(00)00173-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  4 in total

Review 1.  Anti-inflammatory actions of serine protease inhibitors containing the Kunitz domain.

Authors:  Hiroshi Shigetomi; Akira Onogi; Hirotaka Kajiwara; Shozo Yoshida; Naoto Furukawa; Shoji Haruta; Yasuhito Tanase; Seiji Kanayama; Taketoshi Noguchi; Yoshihiko Yamada; Hidekazu Oi; Hiroshi Kobayashi
Journal:  Inflamm Res       Date:  2010-05-08       Impact factor: 4.575

2.  Kinetics and thermodynamics of 1-anilino-8-naphthalene sulfonate interactions with Urinary Trypsin Inhibitor.

Authors:  Zhenyu Zuo; Handong Fan; Jianjun Guo; Wei Zhou; Lingling Li
Journal:  Protein J       Date:  2012-10       Impact factor: 2.371

Review 3.  Potential of Protein-based Anti-metastatic Therapy with Serpins and Inter α-Trypsin Inhibitors.

Authors:  Ulrich H Weidle; Fabian Birzele; Georg Tiefenthaler
Journal:  Cancer Genomics Proteomics       Date:  2018 Jul-Aug       Impact factor: 4.069

4.  Synergism from the combination of ulinastatin and curcumin offers greater inhibition against colorectal cancer liver metastases via modulating matrix metalloproteinase-9 and E-cadherin expression.

Authors:  Fei Shen; Wen-Song Cai; Jiang-Lin Li; Zhe Feng; Qi-Cai Liu; Huan-Qing Xiao; Jie Cao; Bo Xu
Journal:  Onco Targets Ther       Date:  2014-02-18       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.